Interesting way that both Gilead & Abbvie decided to agree to play fair. one of the articles mentioned that there is no exclusive for either one of the therapy's.
So I would think that both saw a degrading market price because of the competition and worked out a stabilizing price.
Because I am with BCBS / Prime Therapeutics Pharmacy I am seeing in print a actual real time cost reduction, for example my latest Harvoni refill last week says my reduced cost is now $25,673.88 instead of $31,673.88 and that is not the cost Prime Therapeutics pays. Don't' know what the typical mark up for these specialty drugs are but the way the news is being presented sounds like they are getting a much higher discount now. Hopefully we will still see more movement in lesser HCV treatment cost in the coming year.
matt
Tig said
Jan 13, 2015
Excellent news indeed!! Thanks Wayne...
Tig
OldenSlow said
Jan 13, 2015
"There has been a substantial reduction in the net price of both of these drugs just in the past few weeks, so sometimes it pays not to go first," said Peter Wickersham, senior vice president of Integrated Care and Specialty, Prime. "It was clear that neither Gilead nor AbbVie wanted to be left off our formulary and the result proved to be significantly better than taking an exclusive position."
Hey Wayne
Interesting way that both Gilead & Abbvie decided to agree to play fair. one of the articles mentioned that there is no exclusive for either one of the therapy's.
So I would think that both saw a degrading market price because of the competition and worked out a stabilizing price.
Because I am with BCBS / Prime Therapeutics Pharmacy I am seeing in print a actual real time cost reduction, for example my latest Harvoni refill last week says my reduced cost is now $25,673.88 instead of $31,673.88 and that is not the cost Prime Therapeutics pays. Don't' know what the typical mark up for these specialty drugs are but the way the news is being presented sounds like they are getting a much higher discount now. Hopefully we will still see more movement in lesser HCV treatment cost in the coming year.
matt
Excellent news indeed!! Thanks Wayne...
Tig
"There has been a substantial reduction in the net price of both of these drugs just in the past few weeks, so sometimes it pays not to go first," said Peter Wickersham, senior vice president of Integrated Care and Specialty, Prime. "It was clear that neither Gilead nor AbbVie wanted to be left off our formulary and the result proved to be significantly better than taking an exclusive position."
Article:
Gilead/AbbVie Preferred Status